Quince Therapeutics, Inc. Income Statement

Income Statement Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -0.96M
Gross Profit -0.96M
Operating items
Research & Development 10.09M60.80M25.18M9.45M18.59M
Selling, General & Administrative 2.03M29.52M26.01M17.70M17.58M
Other Operating Expenses -96.08M-52.59M-40.27M21.11M
Operating Expenses 12.12M90.32M52.02M34.62M57.28M
Operating Income -12.12M-90.32M-52.02M-34.62M-57.28M
EBIT -12.12M-90.32M-52.02M-34.62M-57.28M
Non-operating items
Interest & Investment Income 0.81M0.62M1.07M3.48M2.93M
Other Non Operating Income -0.21M-0.25M-1.00M-0.10M-0.68M
Non Operating Income -0.25M-1.00M-0.10M-0.68M
Net income details
EBT -12.27M-89.70M-51.94M-31.58M-56.74M
Tax Provisions -0.30M-0.20M0.09M
Profit After Tax -12.48M-89.94M-51.66M-31.39M-56.83M
Income from Continuing Operations -12.27M-89.70M-51.64M-31.39M-56.83M
Consolidated Net Income -12.27M-89.70M-51.64M-31.39M-56.83M
Income towards Parent Company -12.27M-89.70M-51.64M-31.39M-56.83M
Net Income towards Common Stockholders -12.27M-89.70M-51.64M-31.39M-56.83M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 26.01M26.85M29.50M29.88M36.13M42.87M44.00M
EBITDA -12.53M-90.34M-51.87M-28.05M-59.91M
Tax Rate 0.00M0.00M